MEBIAS’ business model foresees partnering with select pharmaceutical firms on specific targets, as well as advancing its own molecules into early clinical development.
Potential Investors
The next round of funding from investors will be used to grow our company with the specific goal to discover and progress pre-development candidates for pathway-selective GPCR indications. In hand, we hold highly differentiated mu-opioid receptor pre-development candidates for the treatment of pain. Our technology also enables us to pursue targets in other mechanisms that have strong evidence for yielding signaling-pathway selective compounds that would be devoid of specific side effects.